key: cord-0023321-ufeed5ai
authors: Layunta, Elena; Buey, Berta; Mesonero, Jose Emilio; Latorre, Eva
title: Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis
date: 2021-11-08
journal: Front Endocrinol (Lausanne)
DOI: 10.3389/fendo.2021.748254
sha: a69ea6427abcc6b490c33f98c0d7067a2ab4ab7b
doc_id: 23321
cord_uid: ufeed5ai

Disruption of the microbiota–gut–brain axis results in a wide range of pathologies that are affected, from the brain to the intestine. Gut hormones released by enteroendocrine cells to the gastrointestinal (GI) tract are important signaling molecules within this axis. In the search for the language that allows microbiota to communicate with the gut and the brain, serotonin seems to be the most important mediator. In recent years, serotonin has emerged as a key neurotransmitter in the gut–brain axis because it largely contributes to both GI and brain physiology. In addition, intestinal microbiota are crucial in serotonin signaling, which gives more relevance to the role of the serotonin as an important mediator in microbiota–host interactions. Despite the numerous investigations focused on the gut–brain axis and the pathologies associated, little is known regarding how serotonin can mediate in the microbiota–gut–brain axis. In this review, we will mainly discuss serotonergic system modulation by microbiota as a pathway of communication between intestinal microbes and the body on the microbiota–gut–brain axis, and we explore novel therapeutic approaches for GI diseases and mental disorders.

The gastrointestinal (GI) tract is one of the major defensive organs in individuals because it is continuously exposed to the external environment. In this context, microbial colonization of the intestine during infancy is a major moment for the development of not only the GI tract (1) but also the brain (2) and the immune system (3) . In the last years, numerous researchers have focused their efforts on understanding how intestinal microbiota have the ability to affect the brain and behavior, which has not yet been completely clarified. In this context, the neurotransmitter serotonin (5-hidroxytriptamine, 5-HT) could be the key to resolving this mystery.

The gut-brain axis is a bidirectional crosstalk between the central nervous system (CNS) and the gut. Recently, given the important role in the regulation of gut functions, microbiota are included in the axis. Then, the microbiota-gut-brain axis resides in a coordinated network composed of the CNS, enteric nervous system (ENS), hypothalamic-pituitary-adrenal axis, gut, and microbiota. Both clinical and experimental data suggest that intestinal microbiota play a crucial role in the axis, interacting not only locally with intestinal cells and the ENS but also directly with the CNS through neuroendocrine and metabolic pathways. In fact, germ-free mice studies have proven that the absence of microbial colonization leads to defects in neuron maturation at both CNS and ENS levels, altered expression of neurotransmitters, and gut sensory and motor dysfunctions (4) . Intestinal microbiota dysbiosis has been extensively studied as one of the most important factors in the pathogenesis of inflammatory bowel diseases (IBDs) (5) , including Crohn's disease (CD) and ulcerative colitis (UC). In this context, several studies have described that intestinal serotonin may shape the microbiota composition that protects against the development of IBDs (6) , suggesting the critical relation between the intestinal microbiota and serotonergic system in GI pathologies. However, the role of the microbiota-serotonin interaction would not be limited locally to the gut but also to the CNS. Germ-free mice studies have reported the importance of the microbiota control of the serotonergic system in the CNS (7) or how specific intestinal microorganisms, such as Akkermansia muciniphila, can increase serotonin production in the hippocampus (8) . In this context, recent studies have described the involvement of microbiota in serotonin signaling in CNS disorders such as Alzheimer's or schizophrenia (9) .

Serotonin is a key neurotransmitter, which substantially coordinates the GI physiology and owns critical central functions. Interestingly, serotonin is involved in each component of the microbiota-gut-brain axis, acting as an ideal language for the crosstalk. Microbiota regulate the tryptophan metabolism involved in serotonin production, serotonin acts as a key neurotransmitter in the CNS and ENS, and serotonin receptors play a pivotal role in the hypothalamic-pituitaryadrenal axis.

Here, we highlight recent findings into how microbiota regulate the intestinal and central serotonergic systems, as well as novel clinical approaches to address GI pathologies and brain disorders through the microbiota-gut-brain axis.

In 1940, Vittorio Erspamer discovered serotonin (5-hydroxytryptamine, 5-HT) in the GI tract in rabbits (10) and it was later discovered in the CNS (11) . There are two main serotonergic systems: the central serotonergic system located in the brain and the intestinal serotonergic system in the gut. Both share the same principles of synthesis ("ON mechanism"), internalization and degradation ("OFF mechanism"), and 5-HT signaling through its specific receptors ( Figure 1 ). FIGURE 1 | Schematic representation of brain and intestinal serotonergic systems: "ON/OFF" and signaling mechanisms. "ON" mechanism refers to the synthesis of 5-HT by enterochromaffin cells (EC) in the gut and serotonergic neurons both in the gut and in the central nervous system (CNS). Tryptophan (Trp) is catalyzed by the enzyme tryptophan hydroxylase (TPH), TPH1 in EC cells, and TPH2 in neurons, to synthesize 5-hydroxytryptophan (5-HTP), which is converted to 5-HT by aromatic amino acid decarboxylase (AADC). 5-HT is stored into vesicles through the vesicular monoamine transporter VMAT (VMAT1 in EC cells, and VMAT2 in neurons) and finally released into the extracellular space. 5-HT can bind to different serotonin receptors (5-HTR) or uptake into neurons, enterocytes, or platelets by the serotonin transporter (SERT), ending 5-HT effects ("OFF" mechanism). 5-HT is mostly stored in the dense (d)-granules of platelets; however, the binding of plasma 5-HT to the platelet surface receptor 5-HT 2A initiates the mobilization of intracellular calcium stores for platelet activation, which promotes platelet degranulation, resulting in 5-HT release. Serotonin exerts its effects by signaling mechanisms through the 5-HT receptors located in postsynaptic and presynaptic neurons at CNS and intestinal serotonergic neurons, and in different cell types of gastrointestinal (GI) tract, but also in other systems such as the cardiovascular or immune system.

• The "ON" mechanism is constituted in the gut by enterochromaffin cells and serotonergic neurons of the ENS, while in the CNS, 5-HT is produced only by serotonergic neurons. The primary source of 5-HT is the amino acid L-tryptophan that is catalyzed by the rate-limiting enzyme tryptophan hydroxylase (TPH) to synthesize 5-hydroxytryptophan (5-HTP), which then is converted into serotonin by aromatic amino acid decarboxylase (AAAD) (12) . TPH reaction is a limitative step in the production of 5-HTP and, subsequently, serotonin. It has been described in two isoforms of TPH: TPH1 expressed in enterochromaffin cells and TPH2 in serotonergic neurons from both the ENS and CNS (13). • The "OFF" mechanism in the gut is formed by enterocytes because these intestinal epithelial cells (IECs) internalize 5-HT from the extracellular compartment to the cytoplasm by means of the serotonin transporter (SERT) from the apical and the basolateral membranes. At the CNS level, the "OFF" mechanism is formed by the same serotonergic neurons that synthesize 5-HT because SERT is expressed at terminals and varicosities of serotonergic neurons (14) . SERT is a transmembrane protein grouped in the solute carrier transporters of the SLC6 family that uptakes 5-HT from the extracellular space for subsequent catabolization, reuse, or storage, ending 5-HT effects. SERT is a classic secondary active transporter to which 5-HT binds together with a Na + and a Cl -. Once extracellular serotonin is attached to SERT together with Na + and Cl -, SERT undergoes a conformational change that allows SERT translocation with the release of 5-HT, Na + , and Clinto the cytoplasm of the cell. Once 5-HT is transported inside the cell, intracellular K + binds to SERT and is reoriented toward the extracellular direction, where K + is released and the uptake of 5-HT continues. Then, SERT is not only a key component for the regulation of 5-HT levels, but also an important ion transporter (15). • 5-HT signaling is mediated by specific serotonin receptors that trigger intracellular 5-HT effects ( Table 1) . Scientific community studies on serotonin receptors have recently described a detailed work that classifies the 18 receptors grouped into seven families (5-HT1 to 5-HT7), which are widely expressed not only in the CNS and the GI tract but also in other systems such as the cardiovascular or immune system (79) . As a short summary, the serotonin receptor family consists of G-protein-coupled receptors, with the exception of the 5-HT 3 receptor family (80). 5-HT 1 includes five subtypes: 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , and 5-HT 1F . They are fundamentally involved in CNS disorders such as anxiety. In the case of the GI tract, the 5-HT 1 family is mainly expressed in neurons of the gut submucosa and the myenteric plexus, so their main function is the modulation of GI motility (18) . The 5-HT 2 family involves 5-HT 2A , 5-HT 2B , and 5-HT 2C . 5-HT 2A and 5-HT 2B are expressed in myenteric neurons and neurons from the submucosal plexus in the GI tract, as well as in enterocytes and smooth muscle cells in the gut (36) . Thus, the effect of these receptors is mainly in the GI tract through the regulation of GI motility (81) . However, these receptors are expressed in the brain, where they may control central processes such as memory and cognition (82) or be implicated in CNS disorders such as depression (83) . 5-HT 2C is mainly expressed in the CNS and is involved in several central processes such as the limbic system and motor behavior (38) . The 5-HT 3 family includes five receptors (5-HT 3A-D ) and works as an ion channel similar to GABA receptors. 5-HT 3 receptors are expressed in both the CNS and the GI tract and are involved in several GI processes such as intestinal motility (84) , absorption and secretion (85) , and even 5-HT release from enterochromaffin cells (86) ; in the brain, 5-HT 3 receptors are related with cognition (87) . In this context, 5-HT 3 family dysfunction has been involved in a broad range of pathologies from brain disorders, including psychosis, anxiety, and eating disorders (43) , to GI pathologies such as IBDs (88) . 5-HT 4 receptors are mainly expressed in the gut and participate in intestinal secretion (63) and motility (53) . The 5-HT 5 receptor is the least known from the serotonergic system as some researchers have referred to it for two decades as "the orphan serotonin receptor" (89) . Despite the limited information about this 5-HT receptor, the scientific community has established two subtypes expressed exclusively in the nervous system: 5-HT 5A and 5-HT 5B (90) . These receptors may be involved in several processes, including memory (65) or pain (67) . 5-HT 6 receptors, such as 5-HT 5 receptors, have also been poorly studied. Previous studies in mice have highlighted that it may be important in the GI physiology; however, its importance is not clear (91) . At the CNS level, 5-HT 6 is involved in mental disorders, such as psychosis, and in cognition and learning (70) . Finally, the 5-HT 7 receptor is mainly expressed in the brain but is also located in peripheral organs such as the GI tract (73) . The 5-HT 7 receptor is involved in circadian rhythm (78) , and its dysfunction is important in the onset of depression (92) . In the GI tract, 5-HT 7 modulates SERT activity (75) and intestinal motility (77).

Defense mechanisms in the intestine are widely developed because external agents are in continuous contact with the intestinal epithelium. Innate immunity, throughout several detectors called pattern recognition receptors (PRRs), detects external factors, triggering either tolerant or defense responses to beneficial or pathogenic molecules, respectively. The most important and studied PRRs are microbial detectors: toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD)-like receptors (NLRs) ( Table 2) . TLRs are transmembrane glycoproteins, whereas NLRs are cytosolic receptors. Until now, 11 different TLRs have been identified in humans (TLR1-TLR11) and expressed in both the endosomal membrane (TLR3, 7, 8, and 9) and cell membrane (TLR1, 2, 4, 5, CNS: Hippocampus, neocortex, raphe nuclei, cerebellum, and basal ganglia (16) GI: Neurons of the gut submucosa and the myenteric plexus (17) Other locations: Lymph nodes, thymus and spleen, activated T cells, but not in resting T cells (18, 19) G-protein-coupled receptor for 5-HT that inhibits adenylate cyclase (20) Modulation of the intestinal motility (21) .

Modulation of gastric motility and sensitivity (22) Degranulation of enteric mast cells and release of mediators (23) Inflammation (24) Addiction (25) Behavior (26, 27) Appetite (28) Memory (29) Sleep ( Other locations: Dorsal root ganglia (40) Ligand-gated ion channels (LGIC) that mediates neuronal depolarization and excitation (42) Intestinal motility (43) Inflammation (44) Colonic secretion (45) Intestinal pain and sensitivity (46) Release control of other neurotransmitters: dopamine, GABA or acetylcholine among others (47) .

Regulation of emesis (48) Neurodevelopment (49) Anxiety (50) 5-HT4 CNS: Cortical areas, hippocampus, olfactory tubercles (51) GI: Enteric neurons and smooth muscle cells (52) Other locations: Heart muscle and pituitary gland (Protein Atlas) G-protein-coupled receptor for 5-HT that promote cyclic AMP formation (53) Motility (54) Absorption (55) Intestinal sensitivity (56) Memory and cognition (57, 58) Behavior (59) Feeding ( GI: Gut-associated neurons, but also in enterocyte-like and immune cells in lymphatic tissues (74) Other locations: Spleen, kidney, heart, coronary artery immune cells (73) G-protein-coupled receptor for 5-HT that regulates adenylate cyclase (74) SERT activity modulation (75) Intestinal motility (76) Inflammation (74) Inflammation and repair (77) Circadian rhythm (78) Localization, mechanism, and gastrointestinal (GI) and central nervous system (CNS) functions. 

GI: Immune cells of lamina propria, in the apical membrane of IECs in small intestine and in the basolateral membrane in the colon (107) . Moreover, it can be found in neurons from ENS (101) TLR4 can trigger a Myd88-dependent signaling pathway and a Myd88-independent intracellular signaling pathway driven by TRIF to promote the translocation of nuclear factor-B that regulate the synthesis of inflammatory factors (108) Lipopolysaccharide (109) HMGB1 (110) Fibrinogen (111) HSP60, HSP72, SP22 (112) Lactoferrin (113) TLR5 Plasma membrane CNS: Microglia cells (93) GI: Basolateral side of IECs at the colon, at Paneth cells at the small intestine while in small intestine its expression is restricted to Paneth cells.

TLR5 activation triggers MYD88 and TRIF intracellular signaling that leads to the translocation of NF-kappa-B and inflammatory response (114, 115) Flagellin (116) HMGB1 (117) Hyaluronan (118) TLR7 Endosomal membrane CNS: Microglia cells (93) GI: IECs, plasmacytoid dendritic cells (pDCs), B cells at the lamina propria (119) , and in the myenteric and submucous plexuses of murine intestine and human ileum (101) .

TLR7 activation triggers MYD88 intracellular pathway signaling that leads to the activation NFkappa-B and IRF7 to promote the synthesis of inflammatory factors (120) ssRNA ( PRRs are widely expressed in immune cells (phagocytes, neutrophils, macrophages, or lymphocytes) and nonimmune ones, such as IECs in the GI tract, as well as microglia cells, neurons, or astrocytes in the CNS. PRRs trigger defense-related responses by the detection of specific microbial-associated molecular patterns from microorganisms (MAMPs) or damage-associated molecular patterns (DAMPs) from tissue injury, so we can consider the PRRs the caretakers of our body.

PRRs functioning in IECs are focused on the protection of the intestinal epithelium from potential harmful agents. Thus, and through PRR signaling, the intestine continuously develops the status of physiological inflammation to prevent possible damage and maintain intestinal homeostasis (142) . In the brain, the main role of the PRRs is to detect dangerous molecules that can injure the tissue and trigger repair mechanisms. The brain is protected by the skull, the fluid cerebrospinal, the meninges, and the blood-brain barrier (BBB), which isolates the CNS from the general circulation. However, under pathological conditions, harmful microorganisms can breach the BBB and access the CNS, where the PRRs can trigger defense mechanisms to eliminate the pathogen and to repair the tissue (143) .

PRRs are widely expressed along the GI tract, which differs dramatically between the small intestine and colon (122) .

From all of them, TLR2, TLR3, TLR4, TLR5, and TLR9 seem to be critical in microbial detection and damage repair in the intestine. In the brain, the most studied PRRs, in relation with brain injury and pathogen infection, are TLR2, TLR3, TLR4, and TLR9. However, the scientific community does not discard the relevant importance of other TLRs in this location because they are expressed in several cells from the CNS (125) . PRRs influence the serotonergic system activity and expression ( Table 3 ).

TLR2 is expressed in the GI tract in mononuclear cells of the lamina propria, goblet cells, and enterocytes (96), as well as neurons from the ENS (97). TLR2 is able to detect a broad range of MAMPs from several microorganisms, including Grampositive bacteria through the formation of heterodimers with TLR1 (TLR2/1) and TLR6 (TLR2/6) (157), some fungi such as Candida albicans (158), viruses such as the hepatitis C virus (159) , and some parasites such as Trypanosoma cruzi (160) . At the CNS level, TLR2 is expressed in microglia, astrocytes, and oligodendrocytes (93) . TLR2 in the brain mainly recognizes DAMPs as heat shock family proteins HSP60 and HSP70 (95) or high-mobility group box 1 proteins from dying tumor cells (HMGB1) (98), among others. However, the effect of TLR2 is not limited to immune responses. Previous results carried out in our laboratory have showed that TLR2 activation may modify the intestinal serotonergic system. TLR2 activation could decrease (139) NOD2 recruits RIPK2, which promotes interactions with TRAF, and activates the expression NF-kB and MAPK involved in inflammatory responses (137) Muramyl dipeptide (140) Endoplasmic reticulum stress molecules (138) Calcium (138) Indication of intracellular location, expression at the central nervous system (CNS) and gastrointestinal tract (GI), main intracellular mechanism, main microbial-associated molecular patterns (MAMPs), and main damage-associated molecular patterns (DAMPs). SERT activity due to a reduction in SERT protein expression, with cAMP/PKA and p38/MAPK intracellular pathways being implicated. Moreover, the expected increment of extracellular 5-HT will induce a negative feedback in TLR2 expression, supported by this cross-regulation between the TLR2 and serotonergic system (144) . In fact, TLR2 and TLR4 activation may increase the production of IL-10 in the intestine (161) , which in turn seems to modify SERT (162) . In addition, TLR2 and TLR4 signaling seem to modulate GI motility mediated by 5-HT 2 , 5-HT 3 , 5-HT 4 , and 5-HT 7 receptors (154) . In line with these results, other researchers have found that TLR2 deficiency results in a decrement of gut 5-HT synthesis in vivo and that TLR2 activation upregulates the expression of TPH1 and 5-HT production in the gut (145) . Serotonin-TLR2 relation is not limited to the GI tract, as previous data have highlighted that 5-HT 2B receptor activation downregulates TLR2 expression and TLR3-induced proinflammatory factors in the brain (150 

TLR3 is expressed in IECs, which mainly differentiates doublestranded RNA (dsRNA) from viruses. Surprisingly, TLR3 levels are age dependent because TLR3 expression increases after the suckling-to-weaning transition so as to give protection to the individuals against the virus as a rotavirus (164) . In contrast, central TLR3 expression decreases during neurogenesis of the CNS in the embryo (165) . TLR3 is also able to recognize endogenous mRNA as a DAMP from necrotic cells during intestinal inflammation (102) . At the CNS level, TLR3 is expressed in a broad range of cells, including astrocytes, oligodendrocytes, and microglia cells (93), which is not surprising because viruses can easily reach the brain through other ways different from the BBB, such as neural pathways. Thus, TLR3 can detect dsRNA from the virus in the brain and trigger defense responses to protect the CNS against pathogens. Actually, TLR3 may protect the brain against some viruses such as the herpes simplex virus type 1 (HSV-1) (166) . However, other microorganisms such as the Zika virus can activate TLR3 and induce an exacerbated inflammation and necrosis of the natural defenses of the brain, including the BBB (167). TLR3's role in inflammatory responses may also be exacerbated by its potential pro-oxidant effect. In fact, TLR3 induces protein and lipid oxidation by reducing antioxidant enzymatic activity (168) . TLR3 activation is involved not only in inflammatory and oxidative damage-related responses but also in the modulation of the serotonergic system in the GI tract; TLR3 activation inhibits SERT activity and expression (146) . In contrast, central TLR3 may have an opposite role because recent results have shown that TLR3 activation in a mice model with a brain infection increases SERT activity in astrocytes and therefore reduces extracellular 5-HT levels (147) . In contrast to other TLRs, increased levels of 5-HT will not regulate TLR3 expression (146) ; meanwhile, other studies have reported that the activation of 5-HT 2B receptors may reduce TLR3 expression (150).

TLR4 is one of the most studied PRRs, and its expression can be found in the apical membrane of IECs in the small intestine and in the basolateral membrane in the colon (110) . In the brain, TLR4 is an important PRR in the glia because several researchers have reported its expression (105) ; meanwhile, TLR4 is expressed less often in astrocytes (106) and may be absent in oligodendrocytes (93) . TLR4 recognizes the lipopolysaccharide (LPS), which is the fundamental component of Gram-negative bacteria walls. In this process, the myeloid differentiation factor 2 (MD-2) protein is critical because several studies have found that MD-2 deletion yields to the lack of detection of LPS by TLR4 (169) , suggesting that MD-2 retains TLR4 in the cellular surface to detect LPS due to changes in TLR4 glycosylation (170) . Due to the broad microorganisms that TLR4 can identify through LPS detection, TLR4 has been defined as a gate keeper of microbial homeostasis in the intestine, where it is involved in several defense mechanisms, including the zoonotic Campylobacter (171), Helicobacter pylori (172), or Salmonella (173). TLR4 could also have a regulator role in the serotonergic system. TLR4 modulates contractile response in the intestine and is mediated by serotonin receptors (154) . TLR4 activation inhibits SERT activity through post-transcriptional mechanisms, leading to an increase in extracellular 5-HT (148) . In addition, melatonin, a molecule linked with 5-HT synthesis, may modify intestinal microbiota composition through TLR4 signaling (174) . At the CNS level, TLR4 participates in the detection of pathogens that cause meningitis, such as Neisseria meningitidis (175), where some DAMPs linked to brain damage mediate TLR4 signaling (176) . Interestingly, recent results have pointed out that microbiota and TLR4 signaling are key players in Parkinson's disease, one of the most important degenerative brain pathologies (177) . In this context, previous studies have shown that the lack of TLR4 in the CNS leads to an increase in the central 5-HT level, suggesting the critical regulatory role of TLR4, not only in the GI tract but also in the central serotonergic system (153).

TLR5 seems to be one of the most important TLRs in the GI tract because its expression and activity has been reported in all intestinal segments (122) . In this context, TLR5 is expressed in the basolateral side of IECs from the colon, while in the small intestine, its expression is restricted to Paneth cells. TLR5 recognizes flagellin, a component that enables the motility of several bacteria. Several studies have indicated that flagellin origin is determinant in the defense response against bacteria because flagellin from pathogenic Salmonella typhimurium triggers a more exacerbated immune response than does flagellin from the nonpathogenic bacteria E. coli (178) . In this context, TLR5 is a critical gatekeeper because it may control the intestinal microbiota composition by maintaining a physiological low grade of inflammation in the GI tract (179) . Previous studies have extensively described TLR5 expression in Layunta et al. Serotonin in the Microbiota-Gut-Brain Axis Frontiers in Endocrinology | www.frontiersin.org November 2021 | Volume 12 | Article 748254 microglia cells, where its function may be involved in the inflammatory diseases in the brain comprising bacteria that cause meningitis (180) . However, TLR5 is not only involved in bacterial infection but can also be related with depression. Previous works have described how TLR3, TLR4, TLR5,  TLR7, TLR8 , and TLR9 mRNA expressions in peripheral blood mononuclear cells seem to be increased in patients with depression. The improvement of these patients through the use of selective serotonin reuptake inhibitors (SSRIs) indicates the implication not only of TLR5 but also other PRRs in the modulation of the serotonergic system in brain disorders (181).

TLR7 and TLR8 are closely related PRRs expressed in endosomal membranes that can detect single-stranded RNA (ssRNA) (120). Previous works have described the lack of TLR7 expression in IECs, being mainly expressed in plasmacytoid dendritic cells (pDCs), in B cells at the lamina propria (122) , and in the myenteric and submucous plexuses of murine intestine and human ileum (104) . Meanwhile, TLR8 can be found in macrophages and monocyte-derived DCs (120) . In both cases, it seems that TLR7 and TLR8 could have more importance in other organs, such as the respiratory system, than in the GI tract by recognizing respiratory viruses and triggering inflammatory responses (182) . At the CNS level, TLR7 and TLR8 are mainly expressed in microglia cells. TLR7 acts by regulating the inflammation (183) and modulation of TLR9 expression (184); meanwhile, TLR8 is related with the attenuation of the outgrowth of neurons and the induction of apoptosis (185) . In the GI tract, 5-HT can act by regulating TLR7 in DC through the 5-HT 2B receptor (150) . Moreover, SSRIs seem to decrease the expression of both TLR7 and TLR8 in the CNS (181).

TLR9 is included, together with TLR3, TLR7, and TLR8, in the group of TLRs that is classically expressed in membranes of intracellular organelles such as the endoplasmic reticulum, endosomes, and lysosomes. However, TLR9 can also be detected in endosomal locations (186) . In the GI tract, TLR9 can be expressed in the apical and basolateral membrane of IECs to control homeostasis by means of various intracellular signaling (187) . The intestinal map of TLRs describes TLR9 expression mainly in the lamina propria, and at low levels in GI epithelial cells (122) . TLR9 recognizes unmethylated DNA found generally in microorganisms such as viruses and bacteria (127) . However, TLR9 can also detect host DNA in aberrant locations, such as a DAMP of tissue damage (129) , and it participates in the protection against GI damage and in GI repair (188) . Moreover, TLR9 seems to act as an inhibitor of antimicrobial peptides in the intestine to avoid the colonization of pathogens (189) . Because pathogen-free mice display a higher TLR9 expression in the intestine than germ-free mice do, it has been suggested that beneficial bacteria could modulate TLR9 expression in the GI tract (190) . At the CNS level, TLR9 is expressed in microglia, neurons, and astrocytes (125), mediates immune responses related with brain infections, such as the herpes simplex virus (191) , and attenuates brain injury (192) . Little research has been carried out in the influence of TLR9 over the serotonergic system, and only a few works have indicated that SSRIs may modulate TLR9 mRNA expression in the peripheral blood mononuclear cells of depression patients (181) and will be implicated in the tryptophan catabolism (i.e., the main 5-HT resource) (193) . In fact, preliminary data from our research group indicate that TLR9 could affect SERT activity and expression in an IECs model (194) .

TLR10 is the only PRR without known ligand specificity and biological function. Human TLR10 is encoded on chromosome 4 within the TLR2 gene cluster, together with TLR1, TLR2, and TLR6, suggesting a possible heterodimer TLR2/TLR10 (195) . It has been described that TLR10 could act as an inhibitory receptor that essentially controls TLR2-driven signals (196) . TLR10 is predominantly expressed in tissues rich in immune cells, such as the spleen, lymph node, thymus, tonsil, and lung (197) . Genetic variations found in the TLR10 gene may cause a shift in the levels of pro-and anti-inflammatory responses and enhance the susceptibility to autoimmune diseases, cancers, and infections at the GI tract (198) (199) (200) . Recently, TLR10 has been described in multiple mucosal sites, such as the small intestine, fallopian tubes, eyes, or stomach (198, 201, 202) , suggesting a key role as a pathogen sensor in the mucosa. In the GI tract, TLR10 seems to be a chief component in the immune response to Listeria monocytogenes in IECs. In this context, previous studies have shown that L. monocytogenes affects SERT activity mediated by TLR10, which triggers the activation of a MyD88-dependent intracellular pathway (which may increase 5-HT uptake), and by a MyD88-independent downstream signaling (which may decrease 5-HT uptake), proving a deep involvement of TLRs in the serotonergic mechanism (131) . At the CNS level, TLR10 could be critical for macrophage activity. In fact, microglial cells express TLR10, and this receptor inhibits M1 macrophage cytokines but promotes M2 cytokines, indicating that TLR10 may have a protective role in the brain (130).

Like the TLRs, the NLRs are PRRs that detect both DAMPs and MAMPs triggering immune-related responses to protect the host. However, NLRs differentiate from TLRs with regard to the quality of being cytosolic receptors. NLRs can be classified into two big groups: the NLRC subfamily that encompasses the most popular, including NOD1, NOD2, and NLRC4, and the NLRP subfamily that includes up to 14 PRRs (203).

NOD1 is an intracellular PRR widely expressed in the organism with special relevance in the IECs and in the immune cells from lamina propria in the GI tract, where this PRR detects k-dglutamyl-meso-diaminopimelic acid (iE-DAP) from bacterial peptidoglycan, which can be found in most of the bacterial wall (136) . NOD1 has been involved in the protection of the GI tract against pathogens such as S. typhimurium (204) , Citrobacter rodentium (205) , or H. pylori (206) , among others. Previous works have described the expression of NOD1 in the CNS but at a lower level compared with TLRs (207) , where one of the main functions is the protection against bacterial infections (208) . Interestingly, NOD1 and NOD2 defense effects are only related with immunity because an elegant study has demonstrated that the lack of both receptors in mice leads to signs of stress-induced anxiety, cognitive impairment, and depression, together with increased GI permeability and altered serotonin signaling in the gut, suggesting that NOD1 and NOD2 are novel therapeutic targets for gut-brain axis disorders (156) . Supporting these results, NOD1 activation may decrease SERT activity in IECs due to the diminishment of SERT expression. In turn, 5-HT levels seem also to upregulate NOD1 expression. However, NOD1 could also regulate other PRR expression such as TLR2 and TLR4 (151).

NOD2 is one of the most studied NLRs in the GI tract because polymorphisms in the gene that encodes NOD2 have been strongly associated with IBDs (209) and colorectal cancer (210) . NOD2 is an intracellular PRR expressed in all IECs in the GI tract, which explains its implication in the protection of the intestine against the mentioned pathologies (211). NOD2 detects the bacterial peptidoglycan named muramyl dipeptide (MDP), which allows the identification of several pathogens, including Yersinia (212), Campylobacter (213), and Listeria (214) . At the CNS level, NOD2 seems to play a similar role by detecting pathogens, triggering immune-related responses, and protecting the host (215) . Like NOD1, NOD2 would be an important PRR in the gut-brain axis, especially because of its relation with the serotonergic system in both the CNS and the GI tract (156) . In this sense, bacterial activation of NOD2 may decrease SERT activity and expression, thus leading to an increase in extracellular serotonin, and then serve as a negative feedback modulation of NOD2. In addition, NOD2 not only modulates the serotonergic system directly but also through its interdependence with TLR2 and TLR4 (152) . In fact, the increase of extracellular 5-HT by NOD2 is not only for the downregulation of SERT but also for the increase of enterochromaffin cells that are responsible for 90% of the total 5-HT (216).

In recent years, intestinal microbiota involvement has gained high importance in numerous pathologies, including gut-brain disorders such as IBDs (217), depression (218) , or Alzheimer's disease (219) . In this context, several studies have indicated that 5-HT and serotonergic system modulation by intestinal microbiota are critical in the maintenance of the gut-brain axis (220) (221) (222) . Microbiota can produce tryptophan and tryptamine, directly affecting central 5-HT production (223) . GF mice display a reduction in anxiety-like behavior compared with specific pathogen-free mice, showing a decreased expression of serotonin receptor 1A in the hippocampus (224) . In the GI tract, microbiota increase the production of intestinal 5-HT by increasing TPH1 expression (225) , and, more interestingly, microbiota can also synthesize 5-HT on their own (226) . In agreement with this study, the alteration of microbiota composition and diversity seems to reduce host serotonin levels, increase tryptamine levels, and disrupt the GI immune system (227) . However, it seems that microbiota not only influence 5-HT synthesis and SERT expression but also modulate the expression of some 5-HT receptors (228) . Some pathogenic bacteria such as E. coli can downregulate the activity and expression of SERT in the intestine (229) , and an increase of extracellular 5-HT may induce an adherent-invasive E. coli colonization (230) . Moreover, it has been described that E. coli can produce tryptophan, which will affect 5-HT production (231) . Similarly, some beneficial bacteria such as Lactobacillus seem to degrade tryptophan, affecting central and intestinal 5-HT production (232) . Several studies have shown that germ-free animals have a lower number of enterochromaffin cells compared to those with a standard microbiota (233) . Specific pathogen-free mice display lower 5-HT levels (234) , concluding that microbiota can regulate host 5-HT production not only at the intestinal level but also in the CNS (235) . Apart from that, intestinal microbiota can produce tryptamine, the precursor of 5-HT, independently of the host (226) , which introduces new strategies as to how microbiota will not only modify the intrinsic serotonergic system but also externally modify the levels of 5-HT in the host.

Moreover, intestinal microbiota can modify serotonergic systems by means of their metabolites and affect behavior through the modulation of 5-HT signaling (236) . In this context, some metabolites, including the short-chain fatty acids (SCFAs), are a key component in this modulation and directly affect the gut-brain axis (237) . SCFAs are metabolites from dietary fiber fermentation. They are characterized by having less than six carbon atoms, so they can easily cross membranes, including the BBB. Although studies on the physiological concentrations of SCFAs in the brain are scarce, the three main SCFAs-acetate, propionate, and butyrate-have been detected in cerebrospinal fluid (Human Metabolome Database. Available online at: http://www.hmdb.ca/). In fact, SCFAs could have a critical role in the maintenance and integrity of the BBB (238) . SCFAs seem to regulate the expression levels of TPH1 in the intestine (239) . In our lab, we have described that SCFAs can regulate intestinal SERT activity and expression (240) . Similarly, other bacterial metabolites such as L-lactate seem to control the expression of 5-HT receptors 1B, 1D, and 4 in the CNS (241) . In fact, there is a growing interest in the involvement of microbiota metabolites in the modulation of multiple neurochemical pathways through the highly interconnected gut-brain axis, which could be open novel approaches for gut-brain axis disorders (242).

The serotonergic system is the chief mechanism in the intestine that controls the GI tract (243) and the CNS physiology (244) , with ser otonin be ing one of the mo st imp ortant neurotransmitters in these organs. In addition, 5-HT modulates not only the GI tract and CNS functions, but also their interconnection (i.e., the gut-brain axis). In this context, numerous researchers have claimed that either 5-HT or tryptophan (main 5-HT resource) could be a key factor in gutbrain axis regulation (245) and that its imbalance could trigger pathologies in any of these organs (246) . Interestingly, intestinal microbiota participate directly in 5-HT production, and by means of PRRs activation, microbiota can also affect SERT and regulate 5-HT levels. Moreover, changes in the extracellular 5-HT level may affect PRRs expression in a feedback regulation in order to maintain homeostasis ( Figure 2) .

Interestingly, various pathologies within the gut-brain axis that are apparently unrelated seem to have three common aspects: changes in intestinal microbiota, alterations of the intestinal serotonergic system, and dysfunction of the PRRs ( Table 4 ). In the GI tract, IBDs, including CD and UC, are characterized by changes in the microbiota (345) , alterations in the serotonergic system (346, 347) , and dysfunction of the innate immune system, including TLRs (109) and NLRs (348) . In recent years, novel IBD therapy has focused on treatment to reestablish these three components. Classical control of the intestinal microbiota has focused on antibiotics treatment. However, long-term use of antibiotics in IBDs seems not to resolve the inflammation and is associated with more harm than benefits (349) . Fecal microbial transplantation is one of the most promising novel treatments in IBDs (350) , together with the use of probiotics (351) . In the last century, the use of anti-TNF has also been the most important drug intervention in IBD patients (352) . However, this therapy may be FIGURE 2 | Serotonin (5-HT) communication pathways of the microbiota-gut-brain axis. Serotonin can modulate gastrointestinal (GI) and central nervous system (CNS) functions and is a key network for the gut-brain axis. Microorganisms produce tryptophan, and degrade tryptophan, affecting the central and intestinal 5-HT production. Intestinal microbiota modulate the synthesis of 5-HT and produce 5-HT independently of the host. Microbial associated molecular patterns from microorganisms (MAMPs) through toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD)-like receptors (NLRs) affect directly the serotonergic system. TLR/NLR signaling seems to modulate the activity and the expression of serotonin transporter (SERT) and serotonin receptors (5-HTRs), as well as the 5-HT synthesis in the GI tract. However, this interconnection between TLRs/NLRs and serotonergic system exists in the CNS. In a feedback regulation, 5-HT affects pattern recognition receptor (PRR) expression. In addition, microbial metabolites, such as short chain fatty acids (SCFAs), can promote 5-HT synthesis by enterochromaffin (EC) cells and regulate SERT activity and expression. In the same way, these metabolites can migrate into the bloodstream to reach the brain, and some of them such as L-acetate can modulate the nervous serotonergic system, controlling the expression of 5-HT receptors. (247, 248) Decreased in IBD (249, 250) Decreased in UC and CD (251) Increased in IBS (248) Decreased in IBD (249) Increased in UC and CD (252) Increased in Parkinson's disease (253) (254) (255) Decreased in Alzheimer's disease (251) Decreased in autism spectrum disorder (256, 257) Increased in bipolar disorder (258) Decreased in Parkinson's disease (259) Increased in bipolar disorder (258) Increases TPH1 and decreases SERT expression (260) Increases 5-HT in CNS (261) Increases mucosal 5-HT, and expression of SERT; 5-HTR 2 and 5-HTR 4 (237) Bifidobacterium are decreased in SERT -/mouse (262) Correlated with increased levels of serotonin (263) Microbial manipulation: prebiotic and probiotics in GI disorders (264) (265) (266) Probiotic supplementations in neurodegenerative disorders (267, 268) ;

Microbial manipulation: microbiota transplant in GI disorders (269) (270) (271) (272) Microbial manipulation: microbiota transplant in neurodegenerative disorders (273) (274) (275) (276) Natural products in neurodegenerative disorders (277, 278) Natural products in GI disorders (279, 280) Dietary fibers in GI disorders (281) Nanotechnology and nanotheranostic approach in neurodegenerative disorders (282) (283) (284) Oxidized phospholipidis (285, 286) SCFAs in GI inflammatory disorders (287) (288) (289) CD36 in Alzheimer's disease (290) Firmicutes Clostridiaceae Decreased in IBS (291) Increased in IBD (292, 293) Increased in CD (293) Increased in Parkinson's disease (284, 294) Increased in autism spectrum disorder (256, 257) Decreased in bipolar disorder (258) Increases mucosal 5-HT and EC cells and decreased SERT expression (295) Correlated with increased levels of serotonin (263) Increases SERT expression (296) Lachnospiraceae

Decreased in IBS (291) Decreased in IBD (293, 297) Decreased in UC and CD (298) Not modified in CD (252) Increased in UC (252) Decreased in Parkinson's disease (259, 299, 300) Decreased in autism spectrum disorder (257, 301) Correlated with increased levels of serotonin (263) Increased in Tph -/mice (6) Ruminococcaceae Reduced in IBD (293, 297) Increased in IBS (248, 302) Increased in UC (252) and in CD (293) Reduced in CD (252, 298) Increased in Parkinson's disease (259) Increased in Alzheimer's disease (300) Decreased in autism spectrum disorder (301) Decreased in bipolar disorder (258) Increases 5-HT levels (232) Correlated with levels of serotonin (303) Veillonellaceae Increased in IBS (304, 305) Increased in IBD (305, 306) Increased in UC and CD (252) Decreased in autism spectrum disorder (256) Correlated with increased levels of serotonin (307) Lactobacillaceae Increased in IBS (248) Increased in IBD (297) Decreased in IBD (Lactobacillus) (250) Increased in CD and reduced in UC (252) Increased in Parkinson's disease (253, 255, 308) Decreased in Alzheimer's disease (251) Increased in Alzheimer's disease (300) Increased in autism spectrum disorder (257) Decreases TPH1, 5-THR 3 and 5-HTR 4 expression; and increases SERT expression (260) Increases 5-HT levels (309) Lactobacillus are increased in SERT -/mouse (262) Serotonin-producing bacterial strains (Lactobacillus) ( (291) Increased in IBD (250, 311) Increased in CD (312) and UC (313) Increased in Parkinson's disease (299, 314) Increased in Alzheimer's disease (251) Increased in autism spectrum disorder (257) Enterococcus are increased in SERT -/mouse (262) Staphylococcaceae Increased in IBD (315) Induces 5-HT release (316)

Increased in IBD (318) SERT inhibition (132) Bacteriodetes Bacteroidaceae Increased in IBS (319) Reduced in IBD (297) Reduced in CD (252) and UC (320) Increased in Parkinson's disease (255, 259) Decreased in autism spectrum disorder (257, 321) Increased in state of anxiety (322) Increased in Tph -/mice (6) Increases EC cells (323) Tannerellaceae Decreased in UC (252) Increases 5-HT in hippocampus (324) Rikenellaceae

Decreased in IBS (325) Decreased in IBD (297) Decreased in UC and CD (252) Decreased in Parkinson's disease (259) Increased in autism spectrum disorder (256, 257) Correlated with levels of serotonin (303) Prevotellaceae Decreased in IBS (248) Increased in IBS (304) Increased in IBD (326) Increased in UC and CD (252) Decreased in Parkinson's disease (254, 327) Decreased in autism spectrum disorder (256, 321) Proteobacteria Enterobacteriaceae Increased in IBS (302) Increased in IBD (292, 306) Increased in UC and CD (252) Increased in Parkinson's disease (328) Increased in Alzheimer's disease (300) Increased in autism spectrum disorder (257) Decreases 5-HT and SERT protein (329) Increase 5-HT bioavailability (330) Increases EC cells (331) Serotonin-producing bacterial strains (Escherichia coli K-12) insufficient, and novel studies have indicated that more treatments addressing innate immunity should be carried out. In this context, several studies have indicated that TLR (353) and NLR (354) modulation may help in the treatment of these chronic pathologies. Finally, serotonergic system modulation has been one of the main targets for IBD therapeutics in recent years. In this context, the inhibition of mucosal serotonin (355) or the use of inhibitors for SERT (356) may help in IBDs and thus be considered as a novel therapy for IBDs. Irritable bowel syndrome (IBS) has been described as a gut-brain disorder, where the serotonergic system may be altered in both the intestine and the CNS (357) . Interestingly, intestinal microbiota (358) , as well as SCFAs and 5-HT, are altered in IBS patients (359) . In addition, TLRs and NLRs play a chief role in the pathogenesis of IBS. In fact, several studies have indicated that some PRRs serve as predictive markers for the disease (360) because their expression is increased in the mucosa from IBS patients (361) . Thus, it is not surprising that gut-brain axis modulation in IBS seems to be the most effective therapy in this pathology. Previous studies have shown that SERT regulation (362, 363) and the synthesis of 5-HT (364) may be important in the treatment of IBS. Moreover, serotonin therapy efficiency in IBS is improved through the modulation of microbiota (365, 366) , and previous studies have suggested the immunomodulation of PRRs in this GI disease (367) .

Surprisingly, disorders in the CNS may share the same alterations as the GI pathologies. In this context, serotonergic system alteration may be involved not only in depression and anxiety (368) but also in Parkinson's disease (369) , multiple sclerosis (370), amyotrophic lateral sclerosis (370) , and autism spectrum disorder (371), among others. In fact, conventional treatment for CNS disorders, especially depression, has focused on the modulation of the serotonergic system by means of SSRIs (372) . Important findings have been published in the last years regarding the changes of intestinal microbiota in the CNS pathologies. Recent data have shown that intestinal microbiota may be a critical susceptibility factor in the development of neurological disorders such as Alzheimer's disease, autism spectrum disorder, multiple sclerosis, Parkinson's disease (373) , and depression in particular, where the modulation of the intestinal serotonin by the microbiota seems to be an important trigger (138, 374) . In fact, certain bacteria families modulate tryptophan levels in blood plasma that can cross the BBB and thus influence the central serotonergic system (375) . Within this context, novel therapies of brain pathologies, such as Alzheimer's disease, are focused on the modulation of intestinal microbiota to prevent and ameliorate the development of the pathology (376) . These new studies have shown that the balance of the gut-brain axis is critical in preventing the development of GI and brain disorders mediated by 5-HT (377) . Innate immune receptors, including TLRs and NLRs, could also be a key component in the correct function of the microbiota-gut-brain axis. Previous works have shown that TLR modulation by means of intestinal microbiota may be a critical factor in the development of brain disorders such as Parkinson's disease (177, 378) ; in addition, NLRs may be involved in CNS inflammation and neurodegenerative diseases (379) . New therapeutics have shown that the use of antidepressants may improve the negative regulation of PRRs in some CNS disorders such as depression (380) , especially for TLR4 (381) .

Based on the numerous studies focusing on the gutbrain axis, it is clear that the balance of this bidirectional communication may be important in the prevention of GI and CNS disorders, where the intermodulation of the microbiome, serotonergic system, and innate immunity is critical in maintaining homeostasis. However, more studies are needed to understand the implication of these elements, as well as their modulation as novel therapeutic targets, for the GI and CNS pathologies.

In memoriam: This paper is dedicated to the memory of Professor Ana Isabel Alcalde, a brilliant and enthusiastic (297, 311) Reduced in UC (342) Increased in Parkinson's disease (254, 255, 327) Increased in autism spectrum disorder (256) Increases SERT expression (296) Increases 5-HT in colon and hippocampus (8) Akkermansia are decreased in SERT -/mouse (262) The table summarizes the alterations of bacteria belonging to different bacterial families that are included in the six major phyla of the human gut microbiota (343, 344) scientist, professor, and colleague, as well as our director and mentor, who dedicated her last 20 years to the study of the serotonergic system.

Conceptualization: ElL and BB. Investigation: ElL and BB. Writing-Original Draft Preparation: ElL. Writing-Review and Editing: JM and EvL. Supervision: EvL. All authors contributed to the article and approved the submitted version.

This work was funded by grants from the Foundation for the Study of Inflammatory Bowel Diseases in Aragoń (ARAINF 2012/0567) and the Aragoń Regional Government (A20_20 R). Figures 1 and 2 were created with BioRender.com. We also acknowledge Papercheck Proofreading and Editing Services.

Microbes in Infant Gut Development: Placing Abundance Within Environmental

Gut Microbial Communities Modulating Brain Development and Function

A Weaning Reaction to Microbiota Is Required for Resistance to Immunopathologies in the Adult

The Gut-Brain Axis: Interactions Between Enteric Microbiota, Central and Enteric Nervous Systems

Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease

Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis

Normal Gut Microbiota Modulates Brain Development and Behavior

Modulation of Serotonin Signaling/Metabolism by Akkermansia Muciniphila and Its Extracellular Vesicles Through the Gut-Brain Axis in Mice

Associations Between Gut Microbiota and Alzheimer's Disease, Major Depressive Disorder, and Schizophrenia

Responses of a Molluscan Smooth Muscle to Acetylcholine and 5-Hydroxytryptamine

The Role of Serotonin Beyond the Central Nervous System During Embryogenesis

A Unique Central Tryptophan Hydroxylase Isoform

xPharm: The Comprehensive Pharmacology Reference

Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics

The Distribution of 5-HT1A and 5-HT2A Receptor mRNA in Human Brain

5-Hydroxytryptamine Receptor Subtypes and Their Modulators With Therapeutic Potentials

5-HT-1 Receptors

Role of Serotonin 5-HT1B Receptors in Psychostimulant Addiction

The 5-HT1A Receptor: Signaling to Behavior

Role of 5-HT(1A) and 5-HT(1B) Receptors in the Mediation of Behavior in the Forced Swim Test in Mice

Identification of Cells That Express 5-Hydroxytryptamine1a Receptors in the Nervous Systems of the Bowel and Pancreas

Serotonergic Modulation of Visceral Sensation: Upper Gastrointestinal Tract

Midbrain Raphe 5-HT1A Receptor Activation Alters the Effects of Ghrelin on Appetite and Performance in the Elevated Plus Maze

An Intronless Gene Encoding a Potential Member of the Family of Receptors Coupled to Guanine Nucleotide Regulatory Proteins

Expression of 5HT1a Receptors on Activated Human T Cells. Regulation of Cyclic AMP Levels and T Cell Proliferation by 5-Hydroxytryptamine

Mast Cell Expression of the Serotonin1a Receptor in Guinea Pig and Human Intestine

The Role of 5-HT(1A) Receptors in Learning and Memory

The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine

Involvement of 5-HT1A Receptors in Homeostatic and Stress-Induced Adaptive Regulations of Paradoxical Sleep: Studies in 5-HT1A Knock-Out Mice

Serotonin in the Microbiota-Gut-Brain Axis

Distribution of the Serotonin 5-HT2 Receptor Family mRNAs: Comparison Between 5-HT2A and 5-HT2C Receptors

5-HT(2A) Receptors: Location and Functional Analysis in Intestines of Wild-Type and 5-HT(2A) Knockout Mice

Serotonin 5-HT2B Receptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT Release In Vivo and In Vitro

Serotonin Activates Electrolyte Transport via 5-HT2A Receptor in Rat Colonic Crypt Cells

5-HT System and Cognition

5-HT(2B) Receptors Play a Key Role in Mediating the Excitatory Effects of 5-HT in Human Colon In Vitro

Serotonin and the 5-HT(2B) Receptor in the Development of Enteric Neurons

Chapter

Cloning and Functional Characterization of the Rat Stomach Fundus Serotonin Receptor

Nervous System Distribution of the Serotonin 5-HT3 Receptor mRNA

5-HT3 Receptors

Serotonin Augments Gut Pacemaker Activity via 5-HT3 Receptors

The 5-HT3 Receptor as a Therapeutic Target

Role of Central Vagal 5-HT3 Receptors in Gastrointestinal Physiology and Pathophysiology

Role of Serotonin 5-HT(3) Receptors in Intestinal Inflammation

Serotonin Receptors and Their Role in the Pathophysiology and Therapy of Irritable Bowel Syndrome

Human-Derived Gut Microbiota Modulates Colonic Secretion in Mice by Regulating 5-HT3 Receptor Expression via Acetate Production

The Serotonin 5-HT3 Receptor: A Novel Neurodevelopmental Target

Serotonin and Its Implication for the Management of Irritable Bowel Syndrome

Chapter 38 -Revisiting the Behavioral Genetics of Serotonin: Relevance to Anxiety and Depression

Modifications of 5-HT4 Receptor Expression in Rat Brain During Memory Consolidation

5-HT-4 Receptor

Activation of Colonic Mucosal 5-HT(4) Receptors Accelerates Propulsive Motility and Inhibits Visceral Hypersensitivity

Differential Modulation of the 5-HT(4) Receptor Agonists and Antagonist on Rat Learning and Memory

A Role for the 5-HT(1A), 5-HT4 and 5-HT6 Receptors in Learning and Memory

Expression and Function of 5-HT4 Receptors in the Mouse Enteric Nervous System

The 5-HT4 Receptor Agonist Prucalopride Stimulates Mucosal Growth and Enhances Carbohydrate Absorption in the Ileum of the Mouse

The Absence of 5-HT4 Receptors Modulates Depression-and Anxiety-Like Responses and Influences the Response of Fluoxetine in Olfactory Bulbectomised Mice: Adaptive Changes in Hippocampal Neuroplasticity Markers and 5-HT1A Autoreceptor

Tegaserod, a 5-HT4 Receptor Partial Agonist, Decreases Sensitivity to Rectal Distension in Healthy Subjects

Feeding Disorders in 5-HT4 Receptor Knockout Mice

Distribution of the 5-HT5A Serotonin Receptor mRNA in the Human Brain

The Human 5-Ht5a Receptor Couples to Gi/Go Proteins and Inhibits Adenylate Cyclase in HEK 293 Cells

5-HT Induces Duodenal Mucosal Bicarbonate Secretion via cAMP-and Ca2+-Dependent Signaling Pathways and 5-HT4 Receptors in Mice

Localization of 5-Ht5a Receptor-Like Immunoreactivity in the Rat Brain

Role of 5-HT5A Receptors in the Consolidation of Memory

Distribution of 5-ht(5A), 5-ht(5B), 5-ht(6) and 5-HT(7) Receptor mRNAs in the Rat Brain

Role of Spinal 5-HT5A, and 5-HT1A/ 1B/1D, Receptors in Neuropathic Pain Induced by Spinal Nerve Ligation in Rats

Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor

Serotonin in the Microbiota-Gut-Brain Axis

The Novel Cellular Mechanism of Human 5-HT6 Receptor Through an Interaction With Fyn*

The Medicinal Chemistry of 5-HT6 Receptor Ligands With a Focus on Arylsulfonyltryptamine Analogs

5-HT6 Receptor Antagonist SB-271046 Enhances Extracellular Levels of Monoamines in the Rat Medial Prefrontal Cortex

Immuno-Localization of Serotonin 5-HT6 Receptor-Like Material in the Rat Central Nervous System

Role of 5-HT7 Receptors in the Immune System in Health and Disease

Expression of 5-HT1A and 5-HT7 Receptors in Caco-2 Cells and Their Role in the Regulation of Serotonin Transporter Activity

Serotonin 5-HT7 Receptors Coupled to Induction of Interleukin-6 in Human Microglial MC-3 Cells

5-HT7 Receptor Signaling: Improved Therapeutic Strategy in Gut Disorders

The Role of Serotonin 5-HT7 Receptor in Regulating Sleep and Wakefulness

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-Hydroxytryptamine; Pharmacology and Function

Serotonin Receptor Signaling" in Encyclopedia of Biological Chemistry

5-HT (Serotonin) Physiology and Related Drugs

Effects of the 5-HT Receptor Antagonists GR127935 (5-HT1B/1D) and MDL100907 (5-HT2A) in the Consolidation of Learning

Mice Lacking the Serotonin 5-HT2B Receptor as an Animal Model of Resistance to Selective Serotonin Reuptake Inhibitors Antidepressants

Expression of 5-HT3 Receptors by Extrinsic Duodenal Afferents Contribute to Intestinal Inhibition of Gastric Emptying

5-HT Receptor Subtypes Involved in the Serotonin-Induced Inhibition of L-Leucine Absorption in Rabbit Jejunum

Autoreceptors can Modulate 5-Hydroxytryptamine Release From Porcine and Human Small Intestine In Vitro

The Effects of 5-HT3 Receptor Antagonists on Cognitive Performance in Aged Monkeys

Involvement of 5HT3 Receptors in Anti-Inflammatory Effects of Tropisetron on Experimental TNBS-Induced Colitis in Rat

Pharmacological and Functional Diversity of 5-HT Receptors

The Mouse 5HT5 Receptor Reveals a Remarkable Heterogeneity Within the 5HT1D Receptor Family

Selective 5-HT6 Receptor Ligands: Progress in the Development of a Novel Pharmacological Approach to the Treatment of Obesity and Related Metabolic Disorders

Genetic Knockout and Pharmacological Blockade Studies of the 5-HT7 Receptor Suggest Therapeutic Potential in Depression

Broad Expression of Toll-Like Receptors in the Human Central Nervous System

The Role of TLR2 in Infection and Immunity

HSP60 Plays a Regulatory Role in IL-1beta-Induced Microglial Inflammation via TLR4-P38 MAPK Axis

Microbiota and Innate Immunity in Intestinal Inflammation and Neoplasia

Genetic Analysis of Host Resistance: Toll-Like Receptor Signaling and Immunity at Large

Disulfide HMGB1 Acts via TLR2/4 Receptors to Reduce the Numbers of Oligodendrocyte Progenitor Cells After Traumatic Injury In Vitro

The Endoplasmic Reticulum-Resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-Like Receptor 2/4 Pathway

TICAM-1, an Adaptor Molecule That Participates in Toll-Like Receptor 3-Mediated Interferon-Beta Induction

The dsRNA Binding Site of Human Toll-Like Receptor 3

TLR3 Is an Endogenous Sensor of Tissue Necrosis During Acute Inflammatory Events

Compartmentalizing Intestinal Epithelial Cell Toll-Like Receptors for Immune Surveillance

Toll-Like Receptors 3, 4, and 7 Are Expressed in the Enteric Nervous System and Dorsal Root Ganglia

The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS

Astrocyte TLR4 Activation Induces a Proinflammatory Environment Through the Interplay Between MyD88-Dependent NFkappaB Signaling

MAPK, and Jak1/Stat1 Pathways

Toll-Like Receptor Signaling Pathways

Recognition of Lipopolysaccharide Pattern by TLR4 Complexes

Ligation of Free HMGB1 to TLR2 in the Absence of Ligand Is Negatively Regulated by the C-Terminal Tail Domain

Strategic Compartmentalization of Toll-Like Receptor 4 in the Mouse Gut

Anumba DO. Fibrinogen, an Endogenous Ligand of Toll-Like Receptor 4, Activates Monocytes in Pre-Eclamptic Patients

Identification of Small Heat Shock Protein B8 (HSP22) as a Novel TLR4 Ligand and Potential Involvement in the Pathogenesis of Rheumatoid Arthritis

Lactoferrin Activates Macrophages via TLR4-Dependent and -Independent Signaling Pathways

TRIF Mediates Toll-Like Receptor 5-Induced Signaling in Intestinal Epithelial Cells

Cutting Edge: Bacterial Flagellin Activates Basolaterally Expressed TLR5 to Induce Epithelial Proinflammatory Gene Expression

Structural Basis of TLR5-Flagellin Recognition and Signaling

HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia

TLR5 Participates in the TLR4 Receptor Complex and Promotes MyD88-Dependent Signaling in Environmental Lung Injury

Structural Analysis Reveals That Toll-Like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA

RNA Is Taking Its Toll: Impact of RNA-Specific Toll-Like Receptors on Health and Disease

Recognition of Endogenous Nucleic Acids by the Innate Immune System

A Map of Toll-Like Receptor Expression in the Intestinal Epithelium Reveals Distinct Spatial

DAMPening Inflammation by Modulating TLR Signalling

TLR8-Mediated NF-kappaB and JNK Activation Are TAK1-Independent and MEKK3-Dependent

Toll-Like Receptors in Health and Disease in the Brain: Mechanisms and Therapeutic Potential

Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells

A Toll-Like Receptor Recognizes Bacterial DNA

Toll-Like Receptor 9 Controls Anti-DNA Autoantibody Production in Murine Lupus

Intracellular Localization of Toll-Like Receptor 9 Prevents Recognition of Self DNA But Facilitates Access to Viral DNA

25-Dihydroxyvitamin D3 Facilitates M2 Polarization and Upregulates TLR10 Expression on Human Microglial Cells

Listeria Monocytogenes Inhibits Serotonin Transporter in Human Intestinal Caco-2 Cells

TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection

TLR10 and Its Unique Anti-Inflammatory Properties and Potential Use as a Target in Therapeutics

NLRs in Immune Privileged Sites

The Bacterial Peptidoglycan-Sensing Molecule Pglyrp2 Modulates Brain Development and Behavior

Intestinal Antimicrobial Peptides During Homeostasis

NOD1 and NOD2 Signalling Links ER Stress With Inflammation

NOD1 and NOD2 Activation by Diverse Stimuli: A Possible Role for Sensing Pathogen-Induced Endoplasmic Reticulum Stress

Nod2 Is a General Sensor of Peptidoglycan Through Muramyl Dipeptide (MDP) Detection

NOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease

NOD-Like Receptors: Master Regulators of Inflammation and Cancer

The Role of Pattern Recognition Receptors in Intestinal Inflammation

Pattern Recognition Receptors and Central Nervous System Repair

Intestinal Serotonin Transporter Inhibition by Toll-Like Receptor 2 Activation. A Feedback Modulation

TLR2 Plays a Pivotal Role in Mediating Mucosal Serotonin Production in the Gut

Toll-Like Receptor 3 Activation Affects Serotonin Transporter Activity and Expression in Human Enterocyte-Like Caco-2 Cells

Serotonin in the Microbiota-Gut-Brain Axis

Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome

Lipopolysaccharide Induces Alteration of Serotonin Transporter in Human Intestinal Epithelial Cells

Elevation of Cortical Serotonin Transporter Activity Upon Peripheral Immune Challenge Is Regulated Independently of P38 Mitogen-Activated Protein Kinase Activation and Transporter Phosphorylation

Immunomodulatory Capacity of the Serotonin Receptor 5-HT2B in a Subset of

NOD1 Downregulates Intestinal Serotonin Transporter and Interacts With Other Pattern Recognition Receptors

NOD2 Modulates Serotonin Transporter and Interacts With TLR2 and TLR4 in Intestinal Epithelial Cells

Toll-Like Receptor-4 Regulates Anxiety-Like Behavior

Toll-Like Receptors 2 and 4 Modulate the Contractile Response Induced by Serotonin in Mouse Ileum: Analysis of the Serotonin Receptors Involved

Toll-Like Receptors 2 and 4 Exert Opposite Effects on the Contractile Response Induced by Serotonin in Mouse Colon: Role of Serotonin Receptors

Nod-Like Receptors Are Critical for Gut-Brain Axis Signalling in Mice

Heterodimerization of TLR2 With TLR1 or TLR6 Expands the Ligand Spectrum But Does Not Lead to Differential Signaling

Both TLR2 and TLR4 Are Involved in the Recognition of Candida Albicans. Reply to "TLR2, But Not TLR4, Triggers Cytokine Production by Murine Cells in Response to Candida Albicans Yeasts and Hyphae

Toll-Like Receptor 2 Senses Hepatitis C Virus Core Protein But Not Infectious Viral Particles

Differential Use of TLR2 and TLR9 in the Regulation of Immune Responses During the Infection With Trypanosoma Cruzi

Toll-Like Receptors 2 and 4 Modulate Intestinal IL-10 Differently in Ileum and Colon. United

IL-10 Modulates Serotonin Transporter Activity and Molecular Expression in Intestinal Epithelial Cells

Antiallergic Drug Desloratadine as a Selective Antagonist of 5HT2A Receptor Ameliorates Pathology of Alzheimer's Disease Model Mice by Improving Microglial Dysfunction

Age-Dependent TLR3 Expression of the Intestinal Epithelium Contributes to Rotavirus Susceptibility

Toll-Like Receptor 3 Is a Negative Regulator of Embryonic Neural Progenitor Cell Proliferation

Combating Herpesvirus Encephalitis by Potentiating a TLR3-Mtorc2 Axis

Toll-Like Receptor 3 Mediates West Nile Virus Entry Into the Brain Causing Lethal Encephalitis

TLR2, TLR3, and TLR4 Activation Specifically Alters the Oxidative Status of Intestinal Epithelial Cells

Molecular Genetic Analysis of an Endotoxin Nonresponder Mutant Cell Line: A Point Mutation in a Conserved Region of MD-2 Abolishes Endotoxin-Induced Signaling

MD-2 Is Necessary for the Toll-Like Receptor 4 Protein to Undergo Glycosylation Essential for Its Translocation to the Cell Surface

Toll-Like Receptor-4 Dependent Intestinal and Systemic Sequelae Following Peroral Campylobacter Coli Infection of IL10 Deficient Mice Harboring a Human Gut Microbiota

Essential Role of MD-2 in TLR4-Dependent Signaling During Helicobacter Pylori-Associated Gastritis

Toll-Like Receptor 4 Signalling Through MyD88 Is Essential to Control Salmonella Enterica Serovar Typhimurium Infection, But Not for the Initiation of Bacterial Clearance

Melatonin Controls Microbiota in Colitis by Goblet Cell Differentiation and Antimicrobial Peptide Production Through Toll-Like Receptor 4 Signalling

Live Streptococcus Pneumoniae, Haemophilus Influenzae, and Neisseria Meningitidis Activate the Inflammatory Response Through Toll-Like Receptors 2, 4, and 9 in Species-Specific Patterns

TLR4 Signal Ablation Attenuated Neurological Deficits by Regulating Microglial M1/M2 Phenotype After Traumatic Brain Injury in Mice

Role of TLR4 in the Gut-Brain Axis in Parkinson's Disease: A Translational Study From Men to Mice

Flagellins of Salmonella Typhi and Nonpathogenic Escherichia Coli Are Differentially Recognized Through the NLRC4 Pathway in Macrophages

Intestinal Epithelial Cell Toll-Like Receptor 5 Regulates the Intestinal Microbiota to Prevent Low-Grade Inflammation and Metabolic Syndrome in Mice

Activation of Toll-Like Receptor 5 in Microglia Modulates Their Function Layunta et al. Serotonin in the Microbiota-Gut-Brain Axis and Triggers Neuronal Injury

Antidepressants Normalize Elevated Toll-Like Receptor Profile in Major Depressive Disorder

Role of Toll-Like Receptors in the Pathogenesis of COVID-19

Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses Through Multiple TLRs

Interactions Between TLR7 and TLR9 Agonists and Receptors Regulate Innate Immune Responses by Astrocytes and Microglia

Toll-Like Receptor 8 Functions as a Negative Regulator of Neurite Outgrowth and Inducer of Neuronal Apoptosis

TLR9 Expressed on Plasma Membrane Acts as a Negative Regulator of Human B Cell Response

Maintenance of Colonic Homeostasis by Distinctive Apical TLR9 Signalling in Intestinal Epithelial Cells

TLR9 Is Important for Protection Against Intestinal Damage and for Intestinal Repair

TLR9 Limits Enteric Antimicrobial Responses and Promotes Microbiota-Based Colonisation Resistance During Citrobacter Rodentium Infection

Epithelial Toll-Like Receptors and Their Role in Gut Homeostasis and Disease

TLR2 and TLR9 Synergistically Control Herpes Simplex Virus Infection in the Brain

TLR9 Signalling in Microglia Attenuates Seizure-Induced Aberrant Neurogenesis in the Adult Hippocampus

Toll-Like Receptor 9-Mediated Induction of the Immunosuppressive Pathway of Tryptophan Catabolism

Toll-Like Receptor 9 Activation Affects Intestinal Serotonin Transporter Activity and Expression in Caco-2 Cells

Human TLR10 Is a Functional Receptor, Expressed by B Cells and Plasmacytoid Dendritic Cells, Which Activates Gene Transcription Through Myd88

Human TLR10 Is an Anti-Inflammatory Pattern-Recognition Receptor

Identification of Htlr10: A Novel Human Toll-Like Receptor Preferentially Expressed in Immune Cells

Functional Expression of Pattern Recognition Receptors in Tissues of the Human Female Reproductive Tract

Polymorphisms at Locus 4p14 of Toll-Like Receptors

Confer Susceptibility to Gastric Carcinoma in Helicobacter Pylori Infection

Genetic Polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter Pylori-Associated Gastritis: A Prospective Cross-Sectional Study in Thailand

Toll-Like Receptor 10 in Helicobacter Pylori Infection

Increased Expression of Hepcidin and Toll-Like Receptors 8 and 10 in Viral Keratitis

NOD-Like Receptors: Guardians of Intestinal Mucosal Barriers

Role of Nod1 in Mucosal Dendritic Cells During Salmonella Pathogenicity Island 1-Independent Salmonella Enterica Serovar Typhimurium Infection

Identification of an Innate T Helper Type 17 Response to Intestinal Bacterial Pathogens

Nod1 Responds to Peptidoglycan Delivered by the Helicobacter Pylori Cag Pathogenicity Island

Bacterial Cell Products Signal to Mouse Colonic Nociceptive Dorsal Root Ganglia Neurons

Peptidoglycan Fragment Release From Neisseria Meningitidis

Mutation Spectrum of NOD2 Reveals Recessive Inheritance as a Main Driver of Early Onset Crohn's Disease

NOD2 Mutations and Colorectal Cancer -Where do We Stand?

NOD2 Expression in Intestinal Epithelial Cells Protects Toward the Development of Inflammation and Associated Carcinogenesis

Chronic Yersiniosis Due to Defects in the TLR5 and NOD2 Recognition Pathways

Nucleotide-Binding Oligomerization Domain-Containing Protein 2 Controls Host Response to Campylobacter Jejuni in Il10-/-Mice

Nod2: The Intestinal Gate Keeper

Immunity Against Bacterial Infection of the Central Nervous System: An Astrocyte Perspective

The Vesicle-Associated Function of NOD2 as a Link Between Crohn's Disease and Mycobacterial Infection

Microbiota-Gut-Brain Axis and Its Affect Inflammatory Bowel Disease: Pathophysiological Concepts and Insights for Clinicians

Gut Microbiota's Effect on Mental Health: The Gut-Brain Axis

Serotonin in the Microbiota-Gut-Brain Axis

Brain-Gut-Microbiota Axis in Alzheimer's Disease

Reprint of: Serotonin as a Link Between the Gut-Brain-Microbiome Axis in Autism Spectrum Disorders

The Brain-Gut-Microbiome Axis

Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders

Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion

The Microbiome-Gut-Brain Axis During Early Life Regulates the Hippocampal Serotonergic System in a Sex-Dependent Manner

Indigenous Bacteria From the Gut Microbiota Regulate Host Serotonin Biosynthesis

Discovery and Characterization of Gut Microbiota Decarboxylases That Can Produce the Neurotransmitter Tryptamine

Formula Diet Driven Microbiota Shifts Tryptophan Metabolism From Serotonin to Tryptamine in Neonatal Porcine Colon

A New Role for Microbiota? Dulling the Thrust of Serotonin and 5-HT3 Signaling Cascade

Enteropathogenic Escherichia Coli Infection Inhibits Intestinal Serotonin Transporter Function and Expression

Serotonin Disturbs Colon Epithelial Tolerance of Commensal E. Coli by Increasing NOX2-Derived Superoxide

Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease

Microbial Tryptophan Catabolites in Health and Disease

Metabolomics Analysis Reveals Large Effects of Gut Microflora on Mammalian Blood Metabolites

Regulation of Gut Luminal Serotonin by Commensal Microbiota in Mice

Antibiotics-Induced Modulation of Large Intestinal Microbiota Altered Aromatic Amino Acid Profile and Expression of Neurotransmitters in the Hypothalamus of Piglets

A Microbial Metabolite Synergizes With Endogenous Serotonin to Trigger C. Elegans Reproductive Behavior

Human-Derived Bifidobacterium Dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis

The Gut Microbiota Influences Blood-Brain Barrier Permeability in Mice

Microbiota-Derived Short-Chain Fatty Acids as Modulators of

Peripheral Administration of Lactate Produces Antidepressant-Like Effects

The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication

Role of Serotonin in Gastrointestinal Physiology and Pathology

Influence of Tryptophan and Serotonin on Mood and Cognition With a Possible Role of the Gut-Brain Axis

Tryptophan Metabolism and the Brain-Gut-Microbiome Axis

Novel Aspects of Enteric Serotonergic Signaling in Health and Brain-Gut Disease

Lower Bifidobacteria Counts in Both Duodenal Mucosa-Associated and Fecal Microbiota in Irritable Bowel Syndrome Patients

Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association With Food Components

Analysis of Gut Microbiota in Patients With Parkinson's Disease

A Pilot Microbiota Study in Parkinson's Disease Patients Versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models

Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights From Multi-Omics

Probiotics Modulate Mouse Gut Microbiota and Influence Intestinal Immune and Serotonergic Gene Expression in a Site-Specific Fashion

Systematic Review With Meta-Analysis: The Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome

Epithelial Wound Healing in Inflammatory Bowel Diseases: The Next Therapeutic Frontier

Bifidobacterium Longum W11: Uniqueness and Individual or Combined Clinical Use in Association With Rifaximin

Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease

Changes in the Intestinal Microbiota Are Seen Following Treatment With Infliximab in Children With Crohn's Disease

Analysis of Changes of Intestinal Flora in Elderly Patients With Alzheimer's Disease and Layunta et al. Serotonin in the Microbiota-Gut-Brain Axis

Liver Cancer and Its Correlation With Abnormal Gastrointestinal Motility

Ameliorates Neuroendocrine Alterations Associated With an Exaggerated Stress Response and Anhedonia in Obese Mice

Autism Spectrum Disorders and the Gut Microbiota

Microbiota and Gut-Brain Axis Dysfunction in Autism Spectrum Disorder: Evidence for Functional Gastrointestinal Disorders

A Step Ahead: Exploring the Gut Microbiota in Inpatients With Bipolar Disorder During a Depressive Episode

Serotonin Transporter Deficiency Is Associated With Dysbiosis and Changes in Metabolic Function of the Mouse Intestinal Microbiome

1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Parkinson's Disease in Mouse: Potential Association Between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis

Gut-Brain Axis Cross-Talk and Limbic Disorders as Biological Basis of Secondary TMAU

Role of Gut-Brain Axis, Gut Microbial Composition, and Probiotic Intervention in Alzheimer's Disease

Treatment With Gut Bifidobacteria Improves Hippocampal Plasticity and Cognitive Behavior in Adult Healthy Rats

Microbial Imbalance in Inflammatory Bowel Disease Patients at Different Taxonomic Levels

Compositional and Functional Changes in the Gut Microbiota in Irritable Bowel Syndrome Patients

Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain Through BBB

Alteration of the Fecal Microbiota in Chinese Patients With Parkinson's Disease

Efficacy of Faecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome in a Randomised, Double-Blind, Placebo-Controlled Study

Fecal Microbiota Transplantation for Dysbiosis -Predictable Risks

Gut Microbiome Changes in Patients With Active Left-Sided Ulcerative Colitis After Fecal Microbiome Transplantation and Topical 5-Aminosalicylic Acid Therapy

Faecal Microbiota Transplantation Enhances Efficacy of Immune Checkpoint Inhibitors Therapy Against Cancer

An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-Sectional Study

Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn's Disease

Crosstalk Between Gut and Brain in Alzheimer's Disease: The Role of Gut Microbiota Modulation Strategies

Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation

New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Effects of Akkermansia Muciniphila and Faecalibacterium Prausnitzii on Serotonin Transporter Expression in Intestinal Epithelial Cells

Gut Microbiota in Patients With Parkinson's Disease in Southern China

Microbiota Alterations in Alzheimer's Disease: Involvement of the Kynurenine Pathway and Inflammation

Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges

Jasonia Glutinosa (L.) DC., a Traditional Herbal Tea, Exerts Antioxidant and Neuroprotective Properties in Different In Vitro and In Vivo Systems

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease

Altered Gut Microbiota and Short Chain Fatty Acids in Chinese Children With

The Controversial Role of Human Gut Lachnospiraceae. Microorganisms (2020)

Natural Products: Experimental Efficient Agents for Inflammatory Bowel Disease Therapy

Jasonia Glutinosa (L.) DC., a Traditional Herbal Medicine, Reduces Inflammation, Oxidative Stress and Protects the Intestinal Barrier in a Murine Model of Colitis

A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies

Light-Stress Influences the Composition of the Murine Gut Microbiome, Memory Function, and Plasma Metabolome

Dietary Fibres and IBS: Translating Functional Characteristics to Clinical Value in the Era of Personalised Medicine

Serotonin in the Microbiota-Gut-Brain Axis Frontiers in Endocrinology | www

Differences of Microbiota in Small Bowel and Faeces Between Irritable Bowel Syndrome Patients and Healthy Subjects

The Influence of a Short-Term Gluten-Free Diet on the Human Gut Microbiome

Gegen Qinlian Decoction Enhances Immunity and Protects Intestinal Barrier Function in Colorectal Cancer Patients via Gut Microbiota

Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation

Nanotechnology-Based Drug Delivery for Central Nervous System Disorders

Microbiota and Mucosal Defense in IBD: An Update

Parkinson's Disease-Associated Alterations of the Gut Microbiome Predict Disease-Relevant Changes in Metabolic Functions

Innate Immune Detection of Lipid Oxidation as a Threat Assessment Strategy

Bioactive Lipids and Their Derivatives in Biomedical Applications

Lactobacillus Paracasei Supplementation Prevents Early Life Stress-Induced Anxiety and Depressive-Like Behavior in Maternal Separation Model-Possible Involvement of Microbiota-Gut-Brain Axis in Differential Regulation of MicroRNA124a/132 and Glutamate Receptors

Review Article: Short Chain Fatty Acids as Potential Therapeutic Agents in Human Gastrointestinal and Inflammatory Disorders

Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-Biotics in Inflammatory Bowel Disease

Screening Dietary Fibres for Fermentation Characteristics and Metabolic Profiles Using a Rapid In Vitro Approach: Implications for Irritable Bowel Syndrome

The Function of Lactic Acid Bacteria on Biogenic Amines Production by Food-Borne Pathogens in Arginine Decarboxylase Broth

Gut Microbiota in Parkinson Disease in a Northern German Cohort

CD36 in Alzheimer's Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting

Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients

Differences in the Intestinal Microbiome of Healthy Children and Patients With Newly Diagnosed Crohn's Disease

Gut-Derived Enterococcus Faecium From Ulcerative Colitis Patients Promotes Colitis in a Genetically Susceptible Mouse Host

Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome

Staphylococcal Enterotoxin Induces Emesis Through Increasing Serotonin Release in Intestine and it Is Downregulated by Cannabinoid Receptor 1

SadA-Expressing Staphylococci in the Human Gut Show Increased Cell Adherence and Internalization

The Role of Bacteria in the Inflammatory Bowel Disease Development: A Narrative Review

Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review

Altered Gut Microbial Profile Is Associated With Abnormal Metabolism Activity of

Regulation of Enteroendocrine Cell Networks by the Major Human Gut Symbiont Bacteroides Thetaiotaomicron

Dysbiosis of Gut Microbiota in Polish Patients With Ulcerative Colitis: A Pilot Study

A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome

Involvement of the Microbiota-Gut-Brain Axis in Chronic Restraint Stress: Disturbances of the Kynurenine Metabolic Pathway in Both the Gut and Brain

Methodological Issues in the Study of Intestinal Microbiota in Irritable Bowel Syndrome

Altered Gut Microbiota and Inflammatory Cytokine Responses in Patients With Parkinson's Disease

Sulforaphane Alter the Microbiota and Mitigate Colitis Severity on Mice Ulcerative Colitis Induced by DSS

Short Chain Fatty Acids and Gut Microbiota Differ Between Patients With Parkinson's Disease and Age-Matched Controls

Cronobacter Sakazakii Infection Alters Serotonin Transporter and Improved Fear Memory Retention in the Rat

Increased Immunoendocrine Cells in Intestinal Mucosa of Postinfectious Irritable Bowel Syndrome Patients 3

Years After Acute Shigella Infection-an Observation in a Small Case Control Study

Amine Neuromediators, Their Precursors, and Oxidation Products in the Culture Layunta et al. Serotonin in the Microbiota-Gut-Brain Axis Frontiers in Endocrinology | www

Production of Biogenic Amines by Morganella Morganii, Klebsiella Pneumoniae and Hafnia Alvei Using a Rapid HPLC Method

Dual Role of Helicobacter and Campylobacter Species in IBD: A Systematic Review and Meta-Analysis

Serotonin Modulates Campylobacter Jejuni Physiology and Invitro Interaction With the Gut Epithelium

Characteristics and Risk Factors of Post-Infection Irritable Bowel Syndrome After Campylobacter Enteritis

Helicobacter Pylori Infection and Inflammatory Bowel Disease: A Crosstalk Between Upper and Lower Digestive Tract

The Role of H. Pylori CagA in Regulating Hormones of Functional Dyspepsia Patients

Fusobacterium Nucleatum Causes Microbial Dysbiosis and Exacerbates Visceral Hypersensitivity in a Colonization-Independent Manner

A Simple Fecal Bacterial Marker Panel for the Diagnosis of Crohn's Disease

Ulcerative Colitis: Recent Advances in the Understanding of Disease Pathogenesis. F1000Res (2020) 9:F1000 Faculty Rev-294

Administration of Akkermansia Muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity

What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem Across Age, Environment, Diet, and Diseases. Microorganisms

The Microbiome and Inflammatory Bowel Disease

The Role of 5-HT Dysregulation in Inflammatory Bowel Disease

The Serotonin Reuptake Transporter Is Reduced in the Epithelium of Active Crohn's Disease and Ulcerative Colitis

Emerging Significance of NLRs in Inflammatory Bowel Disease

Antibiotics in IBD: Still a Role in the Biological Era?

Fecal Microbiota Transplantation in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

Systematic Review With Meta-Analysis: The Efficacy of Probiotics in Inflammatory Bowel Disease

25 Years of Anti-TNF Treatment for Inflammatory Bowel Disease: Lessons From the Past and a Look to the Future

Toll-Like Receptor 4 (TLR4) Antagonists as Potential Therapeutics for Intestinal Inflammation

Unleashing the Therapeutic Potential of NOD-Like Receptors

Selective Inhibition of Mucosal Serotonin as Treatment for IBD?

The Effect of Antidepressants on the Course of Inflammatory Bowel Disease

Role of Serotonin in the Pathophysiology of the Irritable Bowel Syndrome

Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review

Alterations in Short-Chain Fatty Acids and Serotonin in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Do Toll-Like Receptors Play a New Role as a Biomarker of Irritable Bowel Syndrome?

Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa From Patients With Irritable Bowel Syndrome

Regulation of the Serotonin Transporter in the Pathogenesis of Irritable Bowel Syndrome

Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome

Targeting Serotonin Synthesis to Treat Irritable Bowel Syndrome

Targeting the Gut Microbiota for the Treatment of Irritable Bowel Syndrome

Modulation of the Gut Microbiota: A Focus on Treatments for Irritable Bowel Syndrome

Role of Toll Like Receptors in Irritable Bowel Syndrome: Differential Mucosal Immune Activation According to the Disease Subtype

Serotonin Receptors in Depression and Anxiety: Insights From Animal Studies

Chapter 50 -Serotonin in Parkinson's Disease" in Handbook of Behavioral Neuroscience

Serotonin: A Mediator of the Gut-Brain Axis in Multiple Sclerosis

Serotonin and Serotonin Transporter Levels in Autistic Children

Modulating the Serotonin System in the Treatment of Major Depressive Disorder

The Gut Microbiome in Neurological Disorders

Serotonin in the Microbiota-Gut-Brain Axis Frontiers in Endocrinology | www

Brain Neurotransmitter Modulation by Gut Microbiota in Anxiety and Depression

The Contribution of Gut Microbiota-Brain Axis in the Development of Brain Disorders

Microbiota Modulation as Preventative and Therapeutic Approach in Alzheimer's Disease

The Microbiota-Gut-Brain Axis: From Motility to Mood

Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease

NLRs as Helpline in the Brain: Mechanisms and Therapeutic Implications

Antidepressants Improve Negative Regulation of Toll-Like Receptor Signaling in Monocytes From Patients With Major Depression

Regulation of Toll-Like Receptor (TLR) Signaling Pathway by Polyphenols in the Treatment of Age-Linked Neurodegenerative Diseases: Focus on TLR4 Signaling

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2021 Layunta, Buey, Mesonero and Latorre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Serotonin in the Microbiota-Gut-Brain Axis